Arteriosclerosis and Thrombosis, Vol 14, 1356-1363, Copyright © 1994 by American Heart Association

ARTICLES

Human leukemia inhibitory factor inhibits development of experimental atherosclerosis

CS Moran, JH Campbell, DL Simmons and GR Campbell
Department of Anatomical Sciences, University of Queensland, Brisbane, Australia.

The effect of human leukemia inhibitory factor (hLIF) on the development of atherosclerosis was investigated in an experimental animal model. Two conditions were examined: one in which lesions could arise because of the influence of both "injury" (cuffed vessel) and diet and one in which only the effect of diet could be significant in other areas of the vasculature (aorta). At time zero, the right carotid artery of rabbits (n = 32) was ensheathed in a soft Silastic cuff, and an osmotic minipump (2-mL capacity; 2.5 microL/h; 28 days) containing either hLIF or saline was inserted into the peritoneal cavity. Rabbits were divided into four groups (n = 8): group 1 received normal diet/saline; group 2, normal diet/LIF (30 micrograms.kg-1.d-1); group 3, 1% cholesterol diet/saline; and group 4, 1% cholesterol diet/LIF (30 micrograms.kg-1.d-1). After 28 days, the cholesterol diet (group 3) resulted in a sixfold increase in plasma cholesterol level compared with group 1 rabbits on a normal diet (3.80 +/- 0.50 versus 0.55 +/- 0.01 mmol/L). This was significantly lower (P = .01) with hLIF treatment in group 4 rabbits (2.80 +/- 0.44 mmol/L). Group 2 rabbits had higher aortic tissue cholesterol levels (1.40 +/- 0.35 mg/g) compared with group 1 rabbits on a normal diet (0.10 +/- 0.06 mg/g) (P = .01), whereas hLIF treatment decreased tissue cholesterol levels by 60% in group 4 rabbits (0.60 +/- 0.05 mg/g) (P = .01). Group 3 rabbits developed lipid-filled lesions covering 63.25 +/- 17.66% of the thoracic aorta surface, whereas lesions were significantly reduced (9.88 +/- 8.79%) (P = .01) with LIF treatment (group 4).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				B. E. Rolfe, S. Stamatiou, C. J. World, L. Brown, A. C. Thomas, J. A. Bingley, N. F. Worth, and J. H. Campbell Leukaemia inhibitory factor retards the progression of atherosclerosis Cardiovasc Res, April 1, 2003; 58(1): 222 - 230. [Abstract] [Full Text] [PDF]

				R. K. Dubey and E. K. Jackson Genome and Hormones: Gender Differences in Physiology: Invited Review: Cardiovascular protective effects of 17{beta}-estradiol metabolites J Appl Physiol, October 1, 2001; 91(4): 1868 - 1883. [Abstract] [Full Text] [PDF]

				R. K. Dubey and E. K. Jackson Estrogen-induced cardiorenal protection: potential cellular, biochemical, and molecular mechanisms Am J Physiol Renal Physiol, March 1, 2001; 280(3): F365 - F388. [Abstract] [Full Text] [PDF]

				J. H. Campbell, J. L. Efendy, N. J. Smith, and G. R. Campbell Molecular Basis by Which Garlic Suppresses Atherosclerosis J. Nutr., March 1, 2001; 131(3): 1006S - 1009. [Abstract] [Full Text]

				M. Vasse, J. Pourtau, V. Trochon, M. Muraine, J.-P. Vannier, H. Lu, J. Soria, and C. Soria Oncostatin M Induces Angiogenesis In Vitro and In Vivo Arterioscler Thromb Vasc Biol, August 1, 1999; 19(8): 1835 - 1842. [Abstract] [Full Text] [PDF]

				C. S. Moran, J. H. Campbell, and G. R. Campbell Human Leukemia Inhibitory Factor Upregulates LDL Receptors on Liver Cells and Decreases Serum Cholesterol in the Cholesterol-Fed Rabbit Arterioscler Thromb Vasc Biol, July 1, 1997; 17(7): 1267 - 1273. [Abstract] [Full Text]

				C. Ware, M. Horowitz, B. Renshaw, J. Hunt, D Liggitt, S. Koblar, B. Gliniak, H. McKenna, T Papayannopoulou, B Thoma, et al. Targeted disruption of the low-affinity leukemia inhibitory factor receptor gene causes placental, skeletal, neural and metabolic defects and results in perinatal death Development, January 5, 1995; 121(5): 1283 - 1299. [Abstract] [PDF]